In a landmark study, scientists at the Agency of Science, Technology and Research’s (A*STAR) Genome Inst...Read more
Researchers at Okayama University report in the journal Sensors and Actuators B: Chemical that terah...Read more
CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therap...Read more
Japan based B dot Medical Inc. has announced that the company has initiated the development of an ultra-c...Read more
Following 111, Inc.'s strategic partnership with Manulife-Sinochem last year, the Company has reached ano...Read more
ASIA-PACIFIC: MODEST RISE IN HEALTHCARE DEALS
Healthcare private equity tends to be less vulnerable to downturns than other sectors, so it expects demand for assets in Asia-Pacific to increase over the coming years. Buyout funds will invest more in growth-stage assets such as Chinese pharma. And as companies explore ways to increase access to healthcare, emerging trends, such as digital healthcare solutions, should gain steam in China, India and other countries. Investors will continue to seek deals in the provider and medtech sectors, and explore creative ways to deploy capital, such as public-toprivate takeovers. Baker McKenzie Global Transactions Forecast predicts a modest rise of 7 per cent in deals to $331 billion in 2019, as a number of cross-border and domestic megadeals are set to close.